Ocular Inflammatory Complications of Treatment for Metastatic Melanoma

References

• Agarwala S. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9(5):587–595. doi:10.1586/ERA.09.25.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang G, Li G. Targeting MAPK pathway in melanoma therapy. Cancer Metastasis Rev. 2013;32(3–4):567–584. doi:10.1007/S10555-013-9433-9.
   PubMed Web of Science ®Google Scholar
• Roberts K, Culleton V, Lwin Z, O’Byrne K, Hughes B. Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol. 2017;13(4):277–288. doi:10.1111/AJCO.12698.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.doi:10.1056/NEJMOA1003466.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. The New England Journal of Medicine. 2019;381(16):1535–1546.doi:10.1056/NEJMOA1910836.
   PubMed Web of Science ®Google Scholar
• Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy. Retina. 2018;38(6):1063–1078. doi:10.1097/IAE.0000000000002181.
   PubMed Web of Science ®Google Scholar
• Fortes BH, Tailor PD, Dalvin LA. Ocular Toxicity of Targeted Anticancer Agents. Drugs. 2021;81(7):771–823. doi:10.1007/S40265-021-01507-Z.
   PubMed Web of Science ®Google Scholar
• Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2020;105(9):1263–1271. doi:10.1136/BJOPHTHALMOL-2020-316970.
   PubMed Web of Science ®Google Scholar
• Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm. 2021;29(1):203–211. doi:10.1080/09273948.2020.1781902.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Cao C, Lu S, et al. MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med. 2009;23(6):771–777.doi:10.3892/IJMM_00000191.
   PubMed Web of Science ®Google Scholar
• Zumelzu C, Alexandre M, Le Roux C, et al. Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1/ programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature. Front Med. 2018;5(SEP). 10.3389/FMED.2018.00268.
   Google Scholar
• Sibaud V, Vigarios E, Siegfried A, Bost C, Meyer N, Pages-Laurent C. Nivolumab-related mucous membrane pemphigoid. Eur J Cancer. 2019;121:172–176. doi:10.1016/J.EJCA.2019.08.030.
   PubMed Web of Science ®Google Scholar
• Coutu A, Farguette F, Jeannin G, Chiambaretta F. Multifocal serous chorioretinopathy secondary to the use of MEK inhibitors: illustration and example of management through two case reports. J Fr Ophtalmol. 2016;39(1). doi:10.1016/j.jfo.2015.05.009.
   Web of Science ®Google Scholar
• Van Dijk EHC, Van Herpen CML, Marinkovic M, et al. Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology. 2015;122(9):1907–1916.doi:10.1016/J.OPHTHA.2015.05.027.
   PubMed Web of Science ®Google Scholar
• Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. JAMA Ophthalmol. 2016;134(8):855–862. doi:10.1001/JAMAOPHTHALMOL.2016.0090.
   PubMed Web of Science ®Google Scholar
• de la Cruz-Merino L, Di Guardo L, Grob JJ, et al. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med. 2017;15(1). 10.1186/S12967-017-1246-0.
   PubMedGoogle Scholar
• Chang M, Kuriakose RK, Xu K, Almeida DRP, Chin EK. Chronic unilateral uveitis with macular edema secondary to dabrafenib for pilocytic astrocytoma. Case Rep Ophthalmol. 2021;12(2):574–577. doi:10.1159/000511340.
   PubMed Web of Science ®Google Scholar
• Sarny S, Neumayer M, Kofler J, El-Shabrawi Y. Ocular toxicity due to trametinib and dabrafenib. BMC Ophthalmol. 2017;17(1). doi:10.1186/S12886-017-0541-0.
   PubMedGoogle Scholar
• Yanagihara RT, Tom ES, Seitzman GD, Saraf SS. A case of bilateral multifocal choroiditis associated with BRAF/MEK inhibitor use for metastatic cutaneous melanoma. Ocul Immunol Inflamm. 2021;1–5. doi:10.1080/09273948.2021.1928714.
   Web of Science ®Google Scholar
• Sun MM, Levinson RD, Filipowicz A, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. 2020;28(2):217–227.doi:10.1080/09273948.2019.1577978.
   PubMed Web of Science ®Google Scholar
• Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect. 2016;6(1). doi:10.1186/S12348-016-0082-3.
   PubMedGoogle Scholar
• Nallapaneni NN, Mourya R, Bhatt VR, Malhotra S, Ganti AK, Tendulkar KK. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Cancer Netw. 2014;12(8):1077–1081. doi:10.6004/JNCCN.2014.0105.
   PubMed Web of Science ®Google Scholar
• Samra KA, Valdes-Navarro M, Lee S, Swan R, Foster CS, Anesi SD. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2015;26(3):e46–e48. doi:10.5301/EJO.5000724.
   Web of Science ®Google Scholar
• Richardson DR, Ellis B, Mehmi I, Leys M. Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. Int J Ophthalmol. 2017;10(7):1183–1186. doi:10.18240/IJO.2017.07.28.
   PubMed Web of Science ®Google Scholar
• Karlin J, Gentzler R, Golen J. Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm. 2018;26(2):283–285. doi:10.1080/09273948.2016.1215473.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chen SJ, Hwang DK, Liu C. Bilateral anterior uveitis after immunotherapy for malignant melanoma. Taiwan J Ophthalmol. 2018;8(3):173–175. doi:10.4103/TJO.TJO_88_17.
   PubMedGoogle Scholar
• Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28(6):854–859.doi:10.1080/09273948.2019.1583347.
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ. Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma. Case Rep Ophthalmol Med. 2013;2013:1–3. doi:10.1155/2013/673796.
   Google Scholar
• Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol. 2015;133(8):965–967. doi:10.1001/JAMAOPHTHALMOL.2015.1128.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–225. doi:10.1016/J.EJCA.2016.02.024.
   PubMed Web of Science ®Google Scholar
• Sagiv O, Kandl TJ, Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthal Plast Reconstr Surg. 2019;35(1):50–52. doi:10.1097/IOP.0000000000001161.
   PubMed Web of Science ®Google Scholar
• Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158(4):831–837.e2. doi:10.1016/J.AJO.2014.07.003.
   PubMed Web of Science ®Google Scholar
• Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745.doi:10.1371/JOURNAL.PONE.0053745.
   PubMed Web of Science ®Google Scholar
• Miyamoto R, Nakashizuka H, Tanaka K, et al. Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report. BMC Ophthalmol. 2020;20(1). doi:10.1186/S12886-020-01495-W.
   Web of Science ®Google Scholar
• de Vries EW, Schauwvlieghe A-S, Haanen JB, de Hoog J. Bilateral serous retinal detachment and uveitis associated with pembrolizumab treatment in metastatic melanoma. Retin Cases Brief Rep. 2020. doi:10.1097/ICB.0000000000000999.
   PubMedGoogle Scholar
• Agemy SA, Mehta AN, Pachydaki SI, Tewari A. Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma. Eur J Ophthalmol. 2014;24(4):629–632. doi:10.5301/EJO.5000423.
   PubMed Web of Science ®Google Scholar
• Niro A, Recchimurzo N, Sborgia A, Guida M, Alessio G. Bilateral ischemic retinal vasculitis in metastatic cutaneous melanoma patient treated with dabrafenib and trametinib: a case report. Ocul Immunol Inflamm. 2018;26(5):783–785. doi:10.1080/09273948.2016.1261166.
   PubMed Web of Science ®Google Scholar
• Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31(3):319–322. doi:10.1016/J.JOCO.2019.05.002.
   PubMed Web of Science ®Google Scholar
• Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS. Combination ipilimumab and nivolumab for metastatic melanoma associated with ciliochoroidal effusion and exudative retinal detachment. JAMA Ophthalmol. 2017;135(12):1455–1457. doi:10.1001/JAMAOPHTHALMOL.2017.4872.
   PubMed Web of Science ®Google Scholar
• O’Bryhim BE, Sychev Y, Rao PK. Bilateral choroidal detachments secondary to ipilimumab and pembrolizumab use. Retin Cases Brief Rep. 2021;15(3):230–233. doi:10.1097/ICB.0000000000000785.
   PubMedGoogle Scholar
• Daniel MC, Heinzelmann S. Simultaneous treatment of severe vemurafenib-induced uveitis and metastatic melanoma. J Clin Exp Ophthalmol. 2016;07(1). doi:10.4172/2155-9570.1000513.
   Google Scholar
• Lim J, Lomax AJ, McNeil C, Harrisberg B. Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: a case report. Ocul Immunol Inflamm. 2018;26(4):628–631. doi:10.1080/09273948.2016.1246666.
   PubMed Web of Science ®Google Scholar
• Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol. 2016;51(1):e4–e6. doi:10.1016/J.JCJO.2015.09.008.
   PubMed Web of Science ®Google Scholar
• De Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol. 2016;68(2):556. doi:10.1002/ART.39406.
   PubMed Web of Science ®Google Scholar
• Heng JS, Kim JM, Kyle Jones D, et al. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. BMJ Open Ophthalmol. 2022;7(1). 10.1136/BMJOPHTH-2021-000889.
   PubMed Web of Science ®Google Scholar
• Apivatthakakul A, Kunavisarut P, Rothova A, Pathanapitoon K. Development of acute vogt–koyanagi–harada-like syndrome during the treatment course with vemurafenib for metastatic melanoma. Ocul Immunol Inflamm. 2020;28(3):505–508. doi:10.1080/09273948.2019.1597896.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–2697. doi:10.1200/JCO.2012.41.6750.
   PubMed Web of Science ®Google Scholar
• Makri OE, Dimitrakopoulos FI, Tsapardoni F, et al. Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. Int J Neurosci. 2020;1–6. doi:10.1080/00207454.2020.1831489.
   Web of Science ®Google Scholar
• Kartal Ö, Ataş E. Bilateral optic neuritis secondary to nivolumab therapy: a case report. Med. 2018;54(5). doi:10.3390/MEDICINA54050082.
   Google Scholar
• Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuro-Ophthalmol. 2015;35(2):144–147. doi:10.1097/WNO.0000000000000217.
   PubMed Web of Science ®Google Scholar
• Hanna KS. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy. 2016;36(11):e183–e188. doi:10.1002/PHAR.1839.
   PubMed Web of Science ®Google Scholar
• Tsui E, Gonzales JA. Retinal vasculitis associated with ipilimumab. Ocul Immunol Inflamm. 2020;28(6):868–870. doi:10.1080/09273948.2019.1610460.
   PubMed Web of Science ®Google Scholar
• Dow ER, Hou K, Ransome S, Abbassi S, Tsui E. Posterior uveitis associated with cemiplimab. Ocul Immunol Inflamm. 2021;1–3. doi:10.1080/09273948.2021.1872649.
   Web of Science ®Google Scholar
• Thomas M, Armenti ST, Bernadete Ayres M, Demirci H. Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol. 2018;136(5):553–556. doi:10.1001/JAMAOPHTHALMOL.2018.0920.
   PubMed Web of Science ®Google Scholar
• Enomoto H, Kato K, Sugawara A, Itabashi M, Kondo M. Case with metastatic cutaneous malignant melanoma that developed Vogt–Koyanagi–Harada-like uveitis following pembrolizumab treatment. Doc Ophthalmol. 2021;142(3):353–360. doi:10.1007/S10633-020-09800-0.
   PubMed Web of Science ®Google Scholar
• Losonczy G, Gijs M, Nuijts RMMA. Nivolumab-induced ulcerative keratitis-a case report. Cornea. 2021;40(5):656–658. doi:10.1097/ICO.0000000000002460.
   PubMed Web of Science ®Google Scholar
• Ryu S, Jun I, Kim TI, Seo KY, Kim EK. Pembrolizumab-induced Stevens–Johnson syndrome with severe ocular complications. Ocular Immunology and Inflammation. 2021;1–3. doi:10.1080/09273948.2021.1896006.
   Web of Science ®Google Scholar